<?xml encoding="utf-8" ?> AstraZeneca PLC AZN announced a strategic collaboration with artificial intelligence-driven drug ...

Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that ...

On Monday, AstraZeneca Plc AZN shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for ...

AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.

AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...

AstraZeneca (AZN) shares have been enjoying a strong bull run ever since falling to a low of $55 in mid-October last year - their lowest value since April 2021. Across a five-year period, overall ...

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...

AstraZeneca stock edged lower despite the US FDA granting accelerated approval for the company’s new breast cancer pill ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

AstraZeneca (NASDAQ:AZN) reported mixed results from a Phase 3 clinical trial for its lung cancer drug datopotamab deruxtecan, or Dato-Dxd, in the treatment of advanced lung cancer. The British ...

Pharma company AstraZeneca has publicly released preclinical data from more than 50 of its medicines in order to find new drug combinations for cancer treatments. The data AstraZeneca released will be ...

Achilles Therapeutics plc has announced the transfer of data and samples from its TRACERx Non-Small Cell Lung Cancer study and its Material Acquisition Platform (MAP) to AstraZeneca for a total ...